June 2024 News Roundup: FDA Approvals, Major Deals, Obesity Research Advances, and More

This summary of major clinical updates from November 2024 covers FDA approvals, the initiation of new clinical trials, notable trial outcomes for key drug candidates, and news on paused and discontinued trials and programs.

GSK and Roche strengthened their pipelines by forming groundbreaking collaborations that target neurodegenerative diseases and transcription factors, respectively. Meanwhile, Pep2Tango Therapeutics introduced a novel obesity treatment approach, and Amgen faced scrutiny over emerging data on its obesity drug candidate MariTide. This roundup covers the details behind these headlines.

To get you up to speed, here’s a recap of July’s molecules on the move, including potential upcoming approvals, key interim trial readouts, new IND submissions, and trial setbacks.

The 2024 SABCS brought together over 10,000 attendees from more than 100 countries, including leading academics, researchers, patient advocates, and healthcare professionals, to showcase state-of-the-art advances in breast cancer research. In our highlights, we will cover exciting clinical trial updates from this year’s symposium, including targeted molecules addressing key pathways such as CDK4, CDK2, and PI3Kα, along with advancements in next-generation oral SERDs (selective estrogen receptor degraders).

In case you missed anything while you were away on summer holiday, here’s a recap of six notable deals from July to get you up to speed.